Osiris Therapeutics to Present at the 4th Annual Cell and Gene Therapy Investor Day

COLUMBIA, Md.–(BUSINESS WIRE)– Osiris
Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and
regenerative medicine company focused on developing and marketing
products to treat conditions in wound care, orthopaedics and sports
medicine, announced today that Dwayne Montgomery, President and Chief
Executive Officer, and Greg Law, Chief Financial Officer are scheduled
to present at the Alliance for Regenerative Medicine’s 4^th
Annual Cell and Gene Therapy Investor Day on Tuesday, March 22, 2016 at
10:00 a.m. ET in New York City.

A live webcast of the presentation may be accessed through the Investors
page of the Company’s website at www.Osiris.com.
A replay of the webcast will be available for one week following the
conference.

Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted
with Piper Jaffray, this one-day, high impact program provides
institutional, strategic and venture investors with unique insight into
the financing hypothesis for advanced therapies-based treatment and
tools. The event includes clinical and commercial experts who are
on-hand to address specific questions regarding the outlook for these
products, as well as offer insight into how cell and gene therapies
could impact the standard of care in key therapeutic areas such as
cardiovascular disease, wound healing and tissue repair, ophthalmology,
neurodegenerative diseases, diabetes and oncology. The program will
include talks by key opinion leaders in the industry, life science
investment experts and analysts covering the sector as well as
presentations by more than 30 leading companies from across the globe.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in
researching, developing and marketing cellular regenerative medicine
products that improve the health and lives of patients and lower overall
healthcare costs. Having developed the world’s first approved stem cell
drug, Osiris works to further advance the medical field. Osiris’
research and development in biotechnology focuses on innovation in
regenerative medicine – including bioengineering, stem cell research and
viable tissue based products. Osiris has achieved commercial success
with products in orthopaedics, sports medicine and wound care, including
BIO^4®, a viable bone matrix, Cartiform^®, a viable
osteochondral allograft, Grafix^®, a cryopreserved placental
membrane, TruSkin^™, a viable human skin allograft and Stravix^™,
a durable placental allograft.

Osiris, Grafix and Cartiform are registered trademarks of Osiris
Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris
Therapeutics, Inc. BIO⁴ is a registered trademark of Stryker
Corporation (NYSE: SYK). More information can be found on the company’s
website, www.Osiris.com.
(OSIR-G)

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international
multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate access
to life-giving advances in regenerative medicine worldwide. ARM also
works to increase public understanding of the field and its potential to
transform human healthcare, providing business development and investor
outreach services to support the growth of its member companies and
research organizations. Prior to the formation of ARM in 2009, there was
no advocacy organization operating in Washington, D.C. to specifically
represent the interests of the companies, research institutions,
investors and patient groups that comprise the entire regenerative
medicine community. Today, ARM has more than 240 members and is the
leading global advocacy organization in this field. To learn more about
ARM or to become a member, visit http://www.alliancerm.org.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as « anticipate, » « believe, »
« continue, » « ongoing, » « estimate, » « expect, » « intend, » « may, » « plan, »
« potential, » « predict, » « project » or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking
statements, but the absence of these words does not necessarily mean
that a statement is not forward-looking. Examples of forward-looking
statements may include, without limitation, statements regarding any of
the following: our product development efforts; our clinical trials and
anticipated regulatory requirements, and our ability to successfully
navigate these requirements; the success of our product candidates in
development; status of the regulatory process for our biologic drug
candidates; implementation of our corporate strategy; our financial
performance; our product research and development activities and
projected expenditures, including our anticipated timeline and clinical
strategy biologic drug candidates and marketed Biosurgery products
(including Grafix, BIO⁴, Cartiform, TruSkin and Stravix); our
cash needs; patents, trademarks and other proprietary rights; the safety
and ability of our products and potential products to treat disease; our
ability to supply a sufficient amount of our marketed products or
product candidates and, if approved or otherwise commercially available,
products to meet demand; our costs to comply with governmental
regulations; our plans for sales and marketing; our plans regarding
facilities; types of regulatory frameworks we expect will be applicable
to our products and potential products; results of our scientific
research; the timing of our amended 2015 filings; and the engagement of
our successor accounting firm. Forward-looking statements are subject to
known and unknown risks and uncertainties and are based on potentially
inaccurate assumptions that could cause actual results to differ
materially from those expected or implied by the forward-looking
statements. Our actual results could differ materially from those
anticipated in forward-looking statements for many reasons, including
the factors described in the section entitled « Risk Factors » in our
Annual Report on Form 10-K and other Periodic Reports filed on Form
10-Q, with the United States Securities and Exchange Commission.
Accordingly, you should not unduly rely on these forward-looking
statements. We undertake no obligation to publicly revise any
forward-looking statement to reflect circumstances or events after the
date of this press release or to reflect the occurrence of unanticipated
events.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160318005497/en/